These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29763709)

  • 21. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
    Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A;
    Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term intensive glycemic and lipid control ameliorates the carotid intima medial thickness in type 2 diabetes mellitus].
    Yang JM; Guo XH; Yu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Dec; 39(6):649-52. PubMed ID: 18087561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of alpha-glucosidase inhibitors on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials.
    Geng DF; Jin DM; Wu W; Fang C; Wang JF
    Atherosclerosis; 2011 Sep; 218(1):214-9. PubMed ID: 21640349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
    Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
    Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
    Zhu S; Su G; Meng QH
    Clin Chem; 2006 Nov; 52(11):2036-42. PubMed ID: 16990410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
    Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of Xiaoji Recipe on stability of carotid artery vulnerable plaque in elderly patients with type 2 diabetes mellitus and type H hypertension].
    Jing-Hui H; Di Z; Ke X; Hai-Yan Y
    Zhongguo Zhong Yao Za Zhi; 2020 Sep; 45(17):4246-4253. PubMed ID: 33164410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
    Rosolová H
    Vnitr Lek; 2015 Nov; 61(11):971-5. PubMed ID: 26652786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation study on the relationship between dyslipidemia and carotid intima-media thickness in patients with diabetes mellitus.
    Guo HJ; Li CC; Bian XY; Hao Q
    Pak J Med Sci; 2023; 39(3):875-879. PubMed ID: 37250570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Echogenecity of the carotid intima-media complex is related to cardiovascular risk factors, dyslipidemia, oxidative stress and inflammation: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
    Andersson J; Sundström J; Gustavsson T; Hulthe J; Elmgren A; Zilmer K; Zilmer M; Lind L
    Atherosclerosis; 2009 Jun; 204(2):612-8. PubMed ID: 19200993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients.
    Cardoso CR; Marques CE; Leite NC; Salles GF
    J Hypertens; 2012 May; 30(5):940-7. PubMed ID: 22495135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.
    de Vries R; Dallinga-Thie GM; Smit AJ; Wolffenbuttel BH; van Tol A; Dullaart RP
    Diabetologia; 2006 Feb; 49(2):398-404. PubMed ID: 16374627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.
    Koopal C; Visseren FLJ; Westerink J; van der Graaf Y; Ginsberg HN; Keech AC
    Diabetes Care; 2018 Jun; 41(6):1244-1250. PubMed ID: 29472432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Carotid artery intima-media thickness (cIMT) in young type 1 diabetic patients in relation to comorbid additional autoimmune diseases and microvascular complications].
    Klonowska B; Charemska D; Jabłońska J; Banach A; Kącka A; Szynkarczuk E; Konopka M; Jarocka-Cyrta E; Załuski D; Głowińska-Olszewska B
    Pediatr Endocrinol Diabetes Metab; 2016; 22(3):. PubMed ID: 28633159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis.
    Amor AJ; Catalan M; Pérez A; Herreras Z; Pinyol M; Sala-Vila A; Cofán M; Gilabert R; Ros E; Ortega E
    Atherosclerosis; 2016 Apr; 247():161-9. PubMed ID: 26921744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
    Plutzky J
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S12-4. PubMed ID: 17935055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study.
    Kozakova M; Natali A; Dekker J; Beck-Nielsen H; Laakso M; Nilsson P; Balkau B; Ferrannini E;
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1409-17. PubMed ID: 23599442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.